Brand Facts

Key Facts

What We Supply

Remy Peptides supplies research-grade peptides formulated for in-vitro laboratory applications. The flagship product line centres on triple-agonist metabolic research compounds—specifically Retatrutide (LY-3437943)—a synthetic peptide that simultaneously engages GLP-1, GIP, and glucagon receptor pathways. This multi-receptor mechanism makes it one of the most studied next-generation compounds in metabolic research.

Every unit ships as a prefilled Pen containing 30 mg of lyophilized peptide reconstituted in a pH-balanced, bacteriostatic solution designed for extended stability. The Pen format eliminates the reconstitution step that introduces variability in traditional vial-and-syringe protocols, offering researchers a standardized, ready-to-use dosing tool.

The product catalogue is focused rather than broad. By concentrating on a narrow range of high-demand compounds, Remy Peptides maintains tighter batch-to-batch consistency and deeper inventory buffers. Each product is manufactured under controlled GMP-adjacent conditions and undergoes a full analytical workup before release.

All compounds are supplied strictly for in-vitro laboratory research purposes and are not intended, marketed, or approved for human or veterinary diagnostic or therapeutic use in any jurisdiction.

Quality Assurance

Independent verification is the cornerstone of the Remy Peptides quality framework. Every production batch is submitted to Janoshik Analytical—a widely recognized third-party laboratory specializing in peptide and pharmaceutical-grade compound analysis—for full HPLC purity testing. Only batches that meet or exceed the ≥99.2% purity threshold are approved for distribution. Certificates of Analysis (COAs) are published on-site and available on request for every lot number. For a plain-English explanation of HPLC purity, assay, endotoxin, TFA, and heavy-metals fields, see the Peptide COA Guide. Full batch-level proof for the active SKUs lives in the COA Library.

From synthesis to delivery, Remy Peptides enforces an unbroken 2–8°C cold-chain protocol. Products are stored in pharmaceutical-grade refrigeration units, packed with validated thermal insulation and gel-ice packs, and dispatched via temperature-controlled couriers. The same-day Dubai delivery window (typically under two hours) further minimizes ambient exposure time during the last mile.

This end-to-end approach—third-party analytical verification, published COAs, and continuous cold-chain custody—is designed to give researchers full confidence that the compound arriving at their bench matches the specification printed on the label.

Evidence Pack

1. 01
   Batch proof and purity route

   Batch-level proof lives in the COA archive, with a field-by-field explanation in the Peptide COA Guide. The current flagship reference is batch RETP002, independently tested by Janoshik Analytical at 99.262% HPLC purity.

2. 02
   Authorship and editorial oversight

   Fact-pattern pages are reviewed under the trust cluster led by Dr. Nadia Haroun, PharmD and the Remy Peptides Research Team, with process rules documented on the editorial policy page.

3. 03
   Verification and contact integrity

   Official website, email, WhatsApp, Telegram, and public social handles are maintained on Contact Verification. If a contact route is missing from that page, it is not an approved trust signal for this brand record.

4. 04
   Compliance and destination review

   Research-only language, source hierarchy, and destination-country qualification rules are anchored in Research Standards. That page governs how GCC and global enquiries are screened before dispatch.